

Contents

1	Pathogenesis of Cardiac Diseases	1
1.1	Gene Transcription in Cardiovascular Diseases	2
1.1.1	Chromatin Remodelers	2
1.1.2	Gene Transcription and Mechanical Factors	5
1.1.3	Gene Transcription in Cardiomyocytes and Glucocorticoids	8
1.2	Myocardial Regeneration Capacity	8
1.2.1	Cardiomyocytes Before and After Birth	9
1.2.2	Oxygen Concentration and Cardiomyocyte Proliferation	10
1.2.3	Mechanical Load and Cardiomyocyte Proliferation	10
1.2.4	Growth Factors and Cardiomyocyte Proliferation	11
1.2.5	Extracellular Matrix and Cardiomyocyte Proliferation	11
1.2.6	MicroRNAs and Cardiomyocyte Proliferation	12
1.2.7	Genetic Manipulations and Cardiomyocyte Proliferation	12
1.2.8	Growth Factors and Cardiac Progenitor Proliferation in the Adult Heart	13
1.2.9	Heat Shock Proteins and Cardiac Repair	14
1.3	Molecular Chaperones in Cardiac Diseases	14
1.3.1	General Chaperones	16
1.3.2	Small Chaperones	17
1.3.3	Chaperones of the Endoplasmic Reticulum	17
1.3.4	Protein Degradation and Autophagy	18
1.3.5	Molecular Chaperones and Signal Transduction	18
1.3.6	Molecular Chaperones and Gene Mutations	19
1.3.7	Cardioprotective Chaperones	19
1.4	Control of Cardiomyocyte Fate and Function	20
1.4.1	Nitric Oxide Synthases—Mechanochemotransduction	20
1.4.2	StIM1–Orai1-Mediated Store-Operated Calcium Entry	20
1.4.3	Sphingosine 1-Phosphate	24
1.4.4	Forkhead Box Transcription Factors	24
1.4.5	Regulation by β -Adrenoceptors	25

1.5	Interactions Between Cardiac Cell Populations	27
1.5.1	Examples of Signaling Messengers	28
1.5.2	Mitochondrial Signals	44
1.5.3	Epicardium	57
1.5.4	Cardiac Cell–Endotheliocyte Interactions	58
1.5.5	Adipocyte and Structural Remodeling	66
1.5.6	Interactions Between Cardiac Cells and Resident and Recruited Leukocytes and Platelets	66
1.5.7	Interactions Involving Cardiac Progenitors	77
1.6	Short Peptides and Cardiac Development and Function	78
1.6.1	Apela	78
1.6.2	Small Open Reading Frames and Short Peptides	79
1.6.3	Pseudo-Noncoding RNAs	79
1.7	Pregnancy and Cardiac Function	81
1.7.1	Pregnancy Preparation—Menstrual Cycle and Hormonal Control	81
1.7.2	Uterus	86
1.7.3	Blastocyte	87
1.7.4	Placenta	88
1.7.5	Global Metabolic Changes During Pregnancy	91
1.7.6	Cardiac Metabolism Before and During Pregnancy	92
1.7.7	Cardioprotective and Hypertrophic Pathways During Pregnancy	94
1.7.8	Hemodynamic Changes During Pregnancy	95
1.7.9	Pregnancy-Associated Cardiac Diseases	97
2	Context of Cardiac Diseases	99
2.1	Frequency of Cardiac Diseases	99
2.2	Modeling of Cardiac Diseases	100
2.3	Risk Factors	100
2.3.1	Lifestyle	101
2.3.2	Inflammatory Intestine, Gut Microbiome, and Cardiovascular Disease	111
2.3.3	Psychological Context	114
2.3.4	Smoking	114
2.3.5	Resting Tachycardia	115
2.3.6	Hypertension	115
2.3.7	Diabetes	117
2.3.8	Metabolic Syndrome	118
2.3.9	Altered Sleep	121
2.3.10	Sleep Stages	121
2.3.11	Air Pollution	128

2.4	Genetic Background	133
2.4.1	Genetic Background and Metabolism	134
2.4.2	Genetic Background and Cardiovascular Diseases	134
2.4.3	Genetic Background and Neurotransmission	135
2.4.4	Genetic Background in Lipidic Metabolism	137
2.4.5	Congenital Cardiac Malformations	137
2.5	Hypoxia and Inflammation	141
2.6	Mitochondrion and Inflammation	143
2.7	Oxidative and Nitrative Stresses and Cardiac Diseases	144
2.7.1	Altered Posttranslational Modifications of Sarcomeric Constituents	145
2.7.2	ROS-Dependent Regulation of Sarcomeric Protein Phosphorylation	146
2.7.3	Nitrative Stress	149
2.7.4	Sympathovagal Imbalance	150
2.8	Myocarditis	152
2.8.1	Viral Myocarditis	152
2.8.2	Cardiac Cell Interactions In Myocarditis	152
3	Adverse Cardiac Remodeling	155
3.1	Cardiac Fibrosis	157
3.1.1	Differentiation of Cardiofibroblasts into Myofibroblasts ..	158
3.1.2	Profibrotic Signaling	159
3.1.3	Fibrosis and Between-Cell Crosstalk	162
3.2	Maladaptive Myocardial Hypertrophy	162
3.2.1	Cardiac Cell Interactions in Maladaptive Cardiac Hypertrophy	163
3.2.2	Metabolic Remodeling	166
3.2.3	Gene Transcription and Translation	168
3.2.4	Signaling Remodeling	175
3.2.5	Electrochemical Remodeling	198
3.2.6	Structural Remodeling	199
3.2.7	Pulmonary Arterial Hypertension	207
4	Cardiomyopathies	213
4.1	Genetic Background and Cardiomyopathies	214
4.1.1	Summary of Structures of Sarcomere and Costamere	214
4.1.2	Gene Mutations	221
4.2	Causes of Cardiomyopathies	222
4.2.1	Specific Cardiomyopathies	223
4.3	Classification of Cardiomyopathies	224
4.4	Mitochondria in Cardiomyopathies	224
4.5	Altered Cardiomyocyte Morphology and Function	225
4.5.1	Cardiomyocyte Hypertrophy	225
4.5.2	Cardiac Fibrosis	226

4.5.3	Altered Metabolic Substrate Utilization	226
4.5.4	Apoptosis	227
4.5.5	Altered Signaling	227
4.5.6	Nitric Oxide in Cardiomyopathies	228
4.6	Dilated Cardiomyopathies	230
4.7	Restrictive Cardiomyopathies	232
4.8	Arrhythmogenic Right Ventricular Cardiomyopathy	233
4.9	Diabetic Cardiomyopathy	234
4.10	Dystrophic Cardiomyopathy	235
4.11	Hemochromatic Cardiomyopathy	237
4.12	Hypertrophic Obstructive or Nonobstructive Cardiomyopathies . . .	237
4.13	Idiopathic Dilated Cardiomyopathy	241
4.14	Infective Cardiomyopathy	242
4.15	Ischemic Cardiomyopathy	242
4.16	Left Ventricular Noncompaction Cardiomyopathy	242
4.17	Peripartum and Postpartum Cardiomyopathy	243
4.18	Sarcoidosis-Associated Cardiomyopathy	244
4.19	Tachycardia-Induced Cardiomyopathy	244
4.20	Toxic Cardiomyopathies	245
4.21	Valvular Cardiomyopathy	245
5	Conduction and Rhythm Disorders	247
5.1	Summary of Electrochemical and Mechanical Events	249
5.1.1	Electromechanical Coupling	249
5.1.2	Genesis and Propagation of Action Potentials—Nodal Tissue	250
5.1.3	Myocardial Mechanics and Electrical Activity	253
5.1.4	Sarcolemmal Density of Ion Carriers	254
5.1.5	Complexes Incorporating Ion Channels	256
5.1.6	Cardiomyocyte Tubules	257
5.2	Arrhythmias	257
5.2.1	Types of Arrhythmias	258
5.2.2	Atrial Arrhythmias	262
5.2.3	Ventricular Arrhythmias	275
5.2.4	Genetic Risk Factors and Gene Mutations	279
5.2.5	Conduction Alterations	289
5.3	Experiments and Modeling of Cardiac Electrophysiology	291
5.3.1	Nodal Tissue	291
5.3.2	Transmembrane Ion Distribution and Cardiac Ion Carriers	292
5.3.3	Hodgkin–Huxley Conductance-Based Model	293
5.3.4	Cardiac Structure Representation in Computational Electrophysiology	298
5.3.5	Application of the Hodgkin–Huxley Model to the Heart . .	299
5.3.6	Intercellular Gap Resistance	300

5.3.7	Dispersion of Refractoriness and Reentry	301
5.3.8	Ionic Current Models	303
5.3.9	Bidomain Model	304
5.3.10	Intersubject Variability	305
6	Cardiac Valve Diseases	307
6.1	Aortic Valve Structure	308
6.2	Mitral Valve Structure	310
6.3	Tricuspid Valve Structure	316
6.4	Pulmonary Valve Structure	316
6.5	Left-Sided Valve Failure	317
6.5.1	Mitral Valve Failure	317
6.5.2	Aortic Valve Failure	321
6.6	Right-Sided Valve Failure	327
6.6.1	Tricuspid Valve Failure	327
6.6.2	Pulmonary Valve Failure	329
6.6.3	Cardiac Valve Clinic	330
7	Heart Failure	333
7.1	Risk Factors, Major Causes, and Natural History of Cardiac Deficiency	334
7.2	Structure and Function of Chronic Congestive Heart Failure	335
7.3	Markers of Chronic Heart Failure	336
7.4	Genetic Background and Chronic Heart Failure	338
7.4.1	Troponins	339
7.4.2	Tropomyosin	343
7.4.3	Vinculin and Metavinculin	345
7.4.4	Perturbed Transcriptome	346
7.4.5	Heat Shock Protein- β 1	347
7.4.6	GPCR Kinase	347
7.4.7	Cardiorenal Syndrome	348
7.5	Cardiac Energetics	349
7.5.1	Modeling	349
7.5.2	Regulators of Cardiac Energetics	350
7.5.3	Mitochondrial Dysfunction	350
7.6	Remodeling	352
7.6.1	Transverse Tubule Remodeling in Heart Failure	352
7.6.2	Cell Apoptosis and Necrosis	354
7.6.3	Cardiac Hypertrophy	354
7.6.4	Cardiac Fibrosis	354
7.6.5	Adrenoceptor Compartmentalization	355
7.6.6	Sarcomeric Constituents	355
7.7	Anemia	356
7.8	Cardiac Cachexia	357

7.9	Neurohumoral Agents	358
7.9.1	High Sympathetic Signaling	358
7.9.2	Calcium	366
7.9.3	Renin–Angiotensin Axis	366
7.9.4	Natriuretic Peptides	368
7.9.5	Endothelin-1	369
7.9.6	Relaxins	369
7.9.7	Vascular Endothelium	369
7.9.8	Reactive Oxygen and Nitrogen Species	370
7.9.9	Nuclear Factors of Activated T Cells	371
7.9.10	Periostin	371
7.9.11	Nucleotides	372
7.9.12	Small GTPases	372
7.9.13	Kinases and Phosphatases	372
7.9.14	Erythropoietin and Vascular Endothelial Growth Factor	374
7.9.15	Inflammatory Cytokines	375
7.9.16	Chemokines	375
7.9.17	MicroRNAs in Cardiac Failure	376
7.10	Medical Therapy of Heart Failure	377
8	Coronary Artery Disease and Myocardial Infarction	379
8.1	Coronary Blood Flow	379
8.1.1	Coronary Arteries	380
8.1.2	Coronary Veins	385
8.1.3	Coronary and Cardiac Innervation	386
8.1.4	Coronary Artery Physiology	386
8.2	Clinical Scores	400
8.2.1	Bogaty Score	401
8.2.2	Gensini Score	402
8.2.3	Coronary Artery Surgery Study (CASS) Score	402
8.2.4	Duke–Jeopardy Score	402
8.2.5	Duke Coronary Artery Disease Severity Score	402
8.2.6	Friesinger Score	403
8.2.7	Jenkins Score	403
8.2.8	Sullivan Scores	403
8.2.9	Agatston Score	404
8.2.10	Rentrop Score	404
8.3	Acute Coronary Syndrome	404
8.3.1	Atherosclerotic Plaque Rupture and Erosion	405
8.3.2	Atherosclerotic Plaque Hemorrhage	406
8.3.3	Markers of the Acute Coronary Syndrome	406
8.4	Context	407
8.4.1	Genetic Background, Atherosclerosis, and Myocardial Infarction	407
8.4.2	Inflammation	409

8.4.3	Oxidative Stress and PKB Kinase	411
8.4.4	Impaired Mitochondrial Structure and Function	412
8.4.5	Proteasomal Activity	414
8.4.6	Influence of Obesity	415
8.4.7	Diabetes	415
8.5	Obstructive Epicardial Coronary Artery Disease	416
8.6	Coronary Microvascular Dysfunction	416
8.6.1	Diagnosis	417
8.6.2	Etiology	418
8.6.3	Classification	418
8.6.4	Risk Factors in Type-1 CMVD	419
8.7	Myocardial Ischemia and Infarction	420
8.7.1	Cardiac Cell Interactions In Myocardial Infarction	421
8.7.2	Prognosis	424
8.7.3	Markers of Myocardial Infarction	425
8.7.4	Coronary Thrombosis	425
8.7.5	Precursor Cells	425
8.7.6	Fibroblasts	426
8.7.7	Gap Junction	426
8.7.8	Inflammation in Myocardial Infarction	429
8.7.9	Angiogenesis in the Infarcted Heart	430
8.7.10	Chemical Mediators in Myocardial Infarction	431
8.7.11	Ion Carriers	438
8.7.12	Sympathoexcitatory Reflex	439
8.8	Ischemia–Reperfusion Injury	439
8.8.1	Metabolic Stress in Ischemia–Reperfusion Injury	440
8.8.2	Mitochondria in Ischemia–Reperfusion Events	441
8.8.3	Inflammation and Apoptosis	444
8.8.4	Mediators in Myocardial Ischemia–Reperfusion Injury	448
8.9	Ischemic Preconditioning	460
8.9.1	Molecular Events in Ischemic Tolerance	461
8.9.2	Mitochondrion	463
8.9.3	Gap Junctions	466
8.9.4	Cell Recruitment	466
8.10	Ischemic Postconditioning	467
8.10.1	Mediators of Ischemic Postconditioning	467
8.11	Reinfarction	469
8.11.1	Persistent Inflammation	469
8.11.2	Disturbed Metabolism	469
9	Interventional Medicine and Surgery of Cardiac Diseases	473
9.1	Medical and Surgical Robotics	474
9.2	Electrical Stimulation	475
9.2.1	Implanted Artificial Pacemaker	475
9.2.2	Electroporation-Based Treatment	477

9.3	Surgery	477
9.3.1	Cardiac Surgery	477
9.4	Endovascular Therapy	482
9.4.1	Thermal Ablation of Nodal Tissue	482
9.4.2	Drug-Eluting Stents	483
9.4.3	Depot Stents	486
9.4.4	Resorbable Stents (Scaffolds)	487
9.4.5	Valvate Stents for Heart Valve Replacements	490
9.4.6	Drawbacks of Medical Devices	490
9.4.7	Design of Medical Devices	491
9.5	Stem Cell-Based Regenerative Therapy	491
9.5.1	Mesenchymal and Bone Marrow-Derived Stem Cells	494
9.5.2	Cardiac Resident Progenitor Cells	495
9.5.3	Cell Reprogramming	498
9.6	Mechanophore-Linked Materials	499
9.7	Nanotechnology-Based Therapy	499
9.8	Pharmacogenetics and Pharmacogenomics	501
9.8.1	Drug-Metabolizing Enzymes	502
9.8.2	Drug Transporters	504
9.8.3	Antihypertensive Therapy	504
9.8.4	Drug Receptors and Antilipolytic Therapy	504
9.9	Medical and Surgical Simulators	506
9.10	Modeling, Measurements, and Numerical Simulations	508
9.10.1	Bypass Grafting	508
9.10.2	Mathematical Modeling of Drug Transfer from Stent	511
Conclusion		521
Notation Rules: Aliases and Symbols		523
List of Currently Used Prefixes and Suffixes		531
List of Aliases and Primary Symbols		535
Complementary Lists of Notations		567
References		575
Index		623

Diseases of the Cardiac Pump

Thiriet, M.

2015, XVI, 631 p. 7 illus., 1 illus. in color., Hardcover

ISBN: 978-3-319-12663-0